Including events related to disease progression , adverse events with an outcome of death were reported for @ ( @ % ) of @ patients in the necitumumab plus gemcitabine and cisplatin group and @ ( @ % ) of @ patients in the gemcitabine and cisplatin group ; these were deemed to be related to study drugs in @ ( @ % ) and ten ( @ % ) patients , respectively .